Coherus BioSciences, Inc. - Common Stock (CHRS)
0.9073
+0.0198 (2.23%)
Coherus Bio is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions in the field of immunology and oncology
The company specializes in creating high-quality biologics, including biosimilars—products that are similar to already approved biological medicines. With a commitment to advancing patient care, Coherus Bio engages in research and clinical development to address unmet medical needs, aiming to make healthcare more accessible and affordable through its cutting-edge therapies.
Previous Close | 0.8875 |
---|---|
Open | 0.9000 |
Bid | 0.9000 |
Ask | 0.9462 |
Day's Range | 0.8890 - 0.9500 |
52 Week Range | 0.6603 - 2.640 |
Volume | 1,607,425 |
Market Cap | 104.53M |
PE Ratio (TTM) | 3.945 |
EPS (TTM) | 0.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,796,088 |
News & Press Releases

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter –
By Coherus BioSciences, Inc. · Via GlobeNewswire · March 10, 2025

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · March 3, 2025

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’ investor website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
By Coherus BioSciences, Inc. · Via GlobeNewswire · February 24, 2025

– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
By Coherus BioSciences, Inc. · Via GlobeNewswire · January 22, 2025

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 10, 2025.
By Coherus BioSciences, Inc. · Via GlobeNewswire · January 8, 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
By Coherus BioSciences, Inc. · Via GlobeNewswire · December 18, 2024

Via Benzinga · December 3, 2024

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
Via Benzinga · December 3, 2024

- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
By Coherus BioSciences, Inc. · Via GlobeNewswire · December 3, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
By Coherus BioSciences, Inc. · Via GlobeNewswire · November 27, 2024

Via Benzinga · November 7, 2024

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter –
By Coherus BioSciences, Inc. · Via GlobeNewswire · November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · October 30, 2024

CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

– Net revenue of $65.0 million in Q2 2024 –
By Coherus BioSciences, Inc. · Via GlobeNewswire · August 8, 2024

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus BioSciences, Inc. · Via GlobeNewswire · August 1, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.
Via Talk Markets · June 30, 2024

– Transaction aligns with Coherus’ strategic focus on oncology –
By Coherus BioSciences, Inc. · Via GlobeNewswire · June 27, 2024

Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise
By Coherus BioSciences, Inc. · Via GlobeNewswire · June 5, 2024

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 30, 2024

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 23, 2024

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024.
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 23, 2024

CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

– Net revenue of $77.1 million in Q1 2024 –
By Coherus BioSciences, Inc. · Via GlobeNewswire · May 9, 2024